Fused pyrrole ring or fused pyridine ring compound
The inhibition of Myt1 kinase by fusing pyrrole ring or fused pyridine ring compound has solved the problem of chemotherapy resistance of tumor cells and improved the efficacy of cancer treatment.
Patent Information
- Application Number
- PCT/CN2024/092155
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
The prior art is difficult to effectively inhibit Myt1 kinase, causing tumor cells to obtain chemotherapy drug resistance through DNA damage repair mechanisms, which in turn affects the effect of cancer treatment.
The fused pyrrole ring or fused pyridine ring compound was developed as Myt1 inhibitors to inhibit Myt1 kinase activity, thereby reducing the proliferation ability of tumor cells and used in combination with chemotherapeutic drugs to overcome drug resistance.
By inhibiting Myt1 kinase, it effectively reduces the proliferation ability of tumor cells, enhances the effect of chemotherapy drugs, and improves the efficacy of cancer treatment.
Smart Images

Figure CN2024092155_21112024_PF_FP_ABST
Abstract
Description
Compounds containing fused pyrrole rings or fused pyridine rings Technical Field
[0001] The present invention relates to methods of using inhibitors of membrane-associated tyrosine- and threonine-specific cdc2 inhibitory kinase (Myt1) (gene name PKMYT1), for example, for treating diseases or conditions, such as cancer, and in particular, diseases or conditions that depend on Myt1 activity (e.g., cancers with CCNE1 amplification / overexpression or cancers with FBXW7 mutations). In particular, the present invention relates to compounds containing pyrrole or pyridine rings that act as Myt1 inhibitors, pharmaceutical compositions containing the compounds, and methods of using the compounds. Background Art
[0002] Because human DNA may be constantly damaged by various internal factors (e.g., stalled replication forks, reactive oxygen species) or external factors (ultraviolet light, ionizing radiation, chemicals), in response to these potential dangers, cells have evolved complex mechanisms to counteract these harmful events, preventing them from compromising genomic integrity and causing genomic instability diseases such as cancer. These mechanisms are collectively known as the DNA damage response (DDR).
[0003] The DDR regulates specific DNA repair mechanisms at various stages of the cell cycle by activating various checkpoint pathways, including the G1, S, G2, and mitotic checkpoints. Due to p53 mutations, most cancer cells have lost the G1 checkpoint, making it necessary to rely on the G2 checkpoint for DNA damage correction before entering mitosis and dividing into two daughter cells.
[0004] MYT1 (myelin transcription factor 1) inhibits the cell cycle process by inhibiting the activity of cell cycle-related proteins (such as cyclin A, CDK1 (i.e., cdc2) and CDK2), allowing various tumor cells to repair their DNA damage and continue to proliferate.
[0005] Cdc2 (also known as CDK1) is a cyclin-dependent kinase that controls cell entry into mitosis. During the G2-M transition, cdc2 is dephosphorylated at Tyr-15 and Thr-14, allowing mitosis to proceed. Because phosphorylation of cdc2 at threonine-14 (Thr-14) and tyrosine-15 (Tyr-15) inhibits enzyme activity and prevents premature initiation of mitosis, the timing of cdc2 dephosphorylation is crucial for the initiation of mitosis.
[0006] Cells utilize arrest during the G2 phase of the cell cycle to repair DNA damage before mitosis and avoid cell death. Studies have shown that premature dephosphorylation of cdc2 can lead to mitotic catastrophe and cell death. Myt1 is a key cell cycle regulator during the G2-M phase. Inhibiting Myt1 blocks phosphorylation of cdc2 at Tyr-15 and Thr-14, leading to premature initiation of mitosis and death of rapidly proliferating cells. Furthermore, Myt1 provides a target for inhibiting this mechanism of DNA repair in tumor cells, thereby conferring resistance to chemotherapeutic drugs. In summary, inhibiting Myt1 can reduce tumor cell proliferation and has therapeutic benefits. Myt1 inhibitors can also be used in combination with chemotherapeutic drugs to overcome resistance to chemotherapeutic drugs in tumor cells.
[0007] Therefore, there is still a need to develop an effective Myt1 kinase inhibitor for cancer treatment.
[0008] Summary of the Invention
[0009] One aspect of the present invention is to provide a compound of formula (I):
[0010] wherein ring A, Z1, Z2, Z3, Z4, Z5, Z6, Z7, X, R1, R2, R3, R4, R5, R6 and n are as defined in the specification,
[0011] or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof.
[0012] One aspect of the present invention is to provide a compound of formula (IC):
[0013] wherein R1, n, ring A, ring B, ring C, X and R5 are as defined in the specification,
[0014] or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof.
[0015] Another aspect of the present invention is to provide a compound of formula (II):
[0016] wherein ring A, R1 and n are as defined in the specification.
[0017] The compound of formula (II) is a starting compound for the preparation of the compound of formula (I).
[0018] Another aspect of the present invention is to provide a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate, or hydrate thereof, and one or more pharmaceutically acceptable carriers or excipients. The pharmaceutical composition of the present invention is a Myt1 inhibitor.
[0019] Another aspect of the present invention is to provide use of a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof in the manufacture of a medicament for use as a Myt1 inhibitor.
[0020] Another aspect of the present invention is to provide a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof to inhibit the growth of cancer in the subject. The compound of formula (I) can be used alone or in combination with another therapeutic agent and / or therapy.
[0021] Another aspect of the present invention is to provide a use of a compound of formula (I) in the preparation of a medicament for treating cancer. In one aspect, the medicament further comprises another therapeutic agent, or the medicament is used in combination with another therapeutic agent and / or therapy.
[0022] Another aspect of the present invention is to provide a compound of formula (I) for use in the treatment of cancer.
[0023] Another aspect of the present invention is to provide a pharmaceutical composition for treating cancer, comprising a compound of formula (I).
[0024] Another aspect of the present invention is to provide a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof. DETAILED DESCRIPTION
[0025] The present invention can be more easily understood by referring to the detailed description of the various embodiments of the present invention below, examples and the tables with their related descriptions. Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as those generally understood by those skilled in the art to which the present invention belongs. In addition, it should be understood that those terms as defined in commonly used dictionaries should be interpreted as consistent with their meaning in the context of related art, and, unless clearly defined herein, the terms will not be interpreted with idealized or excessively formal meanings. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments, and are not intended to be limiting.
[0026] definition
[0027] The definitions set forth in this section are intended to clarify terminology used throughout this application.The term "herein" refers to the entire application.
[0028] It must be noted that, as used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, unless the context requires otherwise, singular terms shall include pluralities and plural terms shall include the singular.
[0029] Typically, ranges herein are expressed as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, one embodiment includes the range from one particular value and / or to the other particular value. Similarly, when a value is expressed as an approximation using the word "about," it is understood that the particular value constitutes another embodiment. Additionally, it is understood that the endpoints of each of the ranges are meaningful relative to and independent of the other endpoint. As used herein, the term "about" refers to ±20%, preferably ±10%, and even more preferably ±5%.
[0030] As used herein, the term "optionally substituted" means that substitution is optional. Where substitution is desired, such substitution means that any number of hydrogens on the designated atom are replaced with an option from the designated group, provided that the normal valence of the designated atom is not exceeded and that the substitution results in a stable compound. For example, when the substituent is keto (i.e., =0), then two hydrogens on the atom are replaced. Examples of substituents for a "substituted" group are those present in the exemplary compounds and embodiments disclosed herein and may include, for example, halo, cyano, alkyl, alkoxy, haloalkyl, alkylamino, aminoalkyl, dialkylamino, hydroxyalkyl, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, aminoalkoxy, alkylaminoalkoxy, alkylaminoalkyl, and the like.
[0031] As used herein, the term "halogen" includes fluorine, chlorine, bromine and iodine. "Halo" used as a prefix of a group means that one or more hydrogens on the group are replaced by one or more halogens.
[0032] As used herein, the term "alkyl" refers to a monovalent, saturated, straight-chain or branched hydrocarbon group containing 1 to 12 carbon atoms. Preferably, the alkyl group is a C1-C8 alkyl group. More preferably, the alkyl group is a C1-C6 alkyl group. The alkyl group may be unsubstituted or substituted with one or more substituents. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (including all isomeric forms), hexyl (including all isomeric forms), heptyl (including all isomeric forms), octyl (including all isomeric forms), and the like.
[0033] The term "alkoxy" used alone or as a suffix or prefix refers to a group of the formula -O-(alkyl), wherein alkyl is defined above. Exemplary alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, and the like.
[0034] As used herein, the term "alkenyl" refers to a non-cyclic, monovalent, straight or branched hydrocarbon radical containing one, two or three carbon-carbon double bonds. Non-limiting examples of alkenyl include vinyl, prop-1-enyl, prop-2-enyl, 1-methylvinyl, but-1-enyl, but-2-enyl, but-3-enyl, 1-methylprop-1-enyl, 2-methylprop-1-enyl, and 1-methylprop-2-enyl. Alkenyl may be optionally substituted as defined herein for alkyl.
[0035] "Amin" used as a prefix or suffix to a group means that one or more hydrogens on the group are replaced with one or more amine groups.
[0036] As used herein, the term "alkylamino" refers to a group having the formula -N(RN1)2 or -NHRN1, wherein RN1 is an alkyl group as defined herein. The alkyl portion of the alkylamino group may be optionally substituted as defined for an alkyl group. Each optional substituent on a substituted alkylamino group may itself be unsubstituted or, if valence permits, substituted with an unsubstituted substituent as defined herein for each corresponding group.
[0037] Unless otherwise specified, the term "cycloalkyl" as used herein refers to a saturated monovalent hydrocarbon group with a cyclic configuration, including monocyclic, bicyclic, tricyclic and higher polycyclic alkyl groups (and when polycyclic, including fused and bridged bicyclic and spirocyclic moieties), wherein each cyclic moiety has 3 to 12 carbon atoms. Preferably, the cycloalkyl group has 3 to 8 carbon atoms. More preferably, the cycloalkyl group has 3 to 6 carbon atoms. When the cycloalkyl group contains more than one ring, the ring may be fused or non-fused and includes a bicyclic group. A fused ring generally refers to at least two rings that share two atoms therebetween. Such cycloalkyl groups include, for example, monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, etc., or bicyclic, polycyclic or bridged ring structures such as adamantyl, etc.
[0038] Unless the number of rings is otherwise specified, the term "aryl" refers to a monovalent six- to fourteen-membered monocyclic or bicyclic carbon ring, wherein the monocyclic ring is aromatic and at least one of the rings in the bicyclic ring is aromatic. Representative examples include, but are not limited to, phenyl, biphenyl, naphthyl, indenyl, and the like.
[0039] Unless the number of rings is otherwise specified, "heteroaryl" means a monovalent group of 5 to 14 ring atoms which is a monocyclic, fused bicyclic, or fused tricyclic ring containing one or more, for example, one, two, three, or four, ring heteroatoms independently selected from: -O-, -S(O), n -(n is 0, 1 or 2), -N-, -N(R x )-, and the remaining ring atoms are carbon, wherein the ring containing the monocyclic group is an aromatic ring and at least one of the fused rings containing the bicyclic or tricyclic group is an aromatic ring. One or two ring carbon atoms of any non-aromatic ring containing the bicyclic or tricyclic group may be replaced by a -C(O)-, -C(S)-, or -C(=NH)- group. R x is hydrogen, alkyl, hydroxy, alkoxy, acyl or alkylsulfonyl. Fused bicyclic groups include bridged ring systems. Unless otherwise specified, the valence positions may be located on any atom of any ring of the heteroaryl group as permitted by the valence rules. Specifically, when the valence position is on nitrogen, R x More specifically, the term "heteroaryl" includes, but is not limited to, 1,2,4-triazolyl, oxa-1,3,5-triazolyl, phthalimide, pyridyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, 2,3-dihydro-1H-indolyl (including, for example, 2,3-dihydro-1H-indol-2-yl or 2,3-dihydro-1H-indol-5-yl, etc.), isoindolyl, dihydroindolyl, isoindolyl, benzimidazolyl, benzodioxol-4-yl, benzofuranyl, cinnolinyl, indolizinyl, naphthyridin-3-yl, phthalazin-3-yl, phthalazin-4-yl, pteridinyl , purinyl, quinazolinyl, quinoxalinyl, tetrazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, oxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl (including, for example, tetrahydroisoquinolin-4-yl or tetrahydroisoquinolin-6-yl, etc.), pyrrolo[3,2-c]pyridinyl (including, for example, pyrrolo[3,2-c]pyridin-2-yl or pyrrolo[3,2-c]pyridin-7-yl, etc.), benzopyranyl, thiazolyl, isothiazolyl, thiadiazolyl, benzothiazolyl, benzothiophenyl, and derivatives thereof, or N-oxides or protected derivatives thereof.
[0040] Unless the number of rings is otherwise specified, "heterocyclyl" means a saturated or partially unsaturated monovalent monocyclic radical of 3 to 9 ring atoms or a saturated or partially unsaturated monovalent fused bicyclic radical of 5 to 12 ring atoms, wherein one or more, for example one, two, three or four, ring heteroatoms are independently selected from the group consisting of: -O-, -S(O) ... x -(x is 0, 1 or 2), -N=, -N(R y )-(where R yis hydrogen, alkyl, hydroxy, alkoxy, acyl or alkylsulfonyl), and the remaining ring atoms are carbon. One or two ring carbon atoms can be replaced by -C(O)-, -C(S)- or -C(=NH)- groups. As used herein, the term "heterocyclyl" refers to a monocyclic, bicyclic, tricyclic or tetracyclic ring system having fused, bridged and / or spirocyclic 3-, 4-, 5-, 6-, 7- or 8-members, unless otherwise indicated, containing one, two, three or four heteroatoms independently selected from nitrogen, oxygen and sulfur. Fused bicyclic groups include bridged ring systems. Unless otherwise indicated, the valence of the group can be located on any atom of any ring within the group, as long as the valence rules allow. Specifically, when the valence position is on the nitrogen atom, R y More specifically, the term "heterocyclyl" includes, but is not limited to, piperidinyl, pyrimidinyl, morpholinyl, piperazinyl, azetidinyl, pyrrolidinyl, 2-oxopyrrolidinyl, 2,5-dihydro-1H-pyrrolyl, 4-piperidonyl, 2-oxopiperazinyl, tetrahydropyranyl, 2-oxopiperidinyl, thiomorpholinyl, thimorpholinyl, perhydroazepinyl, pyrazolidinyl, dihydroimidazolyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, oxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolinyl, thiazolidinyl, quinuclidine, isothiazolidinyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolinyl, tetrahydrofuranyl, and tetrahydropyranyl, and derivatives thereof, as well as N-oxides or protected derivatives thereof.
[0041] As used herein, the term "pharmaceutically acceptable salt" refers to derivatives of the disclosed compounds wherein the parent compound is modified by preparing a pharmaceutically acceptable acid or base salt thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali metal or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts formed from the parent compound with, for example, non-toxic inorganic or organic acids. Suitable non-toxic acids include, but are not limited to, inorganic and organic acids such as acetic acid, alginic acid, anthranilic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, formic acid, fumaric acid, furoic acid, galacturonic acid, gluconic acid, glucuronic acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, propionic acid, salicylic acid, stearic acid, succinic acid, p-aminobenzenesulfonic acid, sulfuric acid, tartaric acid, and p-toluenesulfonic acid. Non-limiting examples of salts of the compounds of the present invention include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, 2-hydroxyethanesulfonate, phosphate, hydrogenphosphate, acetate, adipate, alginate, aspartate, benzoate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, succinate, malonate, fumarate, maleate, methanesulfonate, mesitylenesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, trichloroacetate, trifluoroacetate, glutamate, bicarbonate, undecanoate, lactate, citrate, tartrate, gluconate, benzenesulfonate, and p-toluenesulfonate.
[0042] As used herein, the term "geometric isomers" includes, but is not limited to: cis and trans; E- and Z-; c-, t-, and r-; endo and exo; R-, S-, and meso; boat, chair, twist, entangled, and semi-chair; and combinations thereof.
[0043] As used herein, the term "enantiomer" refers to a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemic mixture. The term "enantiomer" is used to refer to a racemic mixture when appropriate. A "diastereomer" is a stereoisomer with at least two asymmetric atoms that are not mirror images of each other. Absolute stereochemistry can be specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer, the stereochemistry at each chiral carbon can be specified by R or S. The split compound can be represented as (+) or (-) according to the direction (right-handed or left-handed) in which it rotates plane polarization at the wavelength of the sodium D line. Certain compounds described herein may contain one or more asymmetric centers or axes, and may therefore produce enantiomers, diastereomers, and other stereoisomeric forms, which can be defined as (R)- or (S)- in terms of absolute stereochemistry. The present invention is intended to include all such possible isomers, including racemic mixtures, optically pure forms, and intermediate mixtures. Optically active (R)- and (S)-isomers can be prepared using chiral synthetic components or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl group, the cycloalkyl substituents may have a cis or trans configuration.
[0044] As used herein, "prodrug" is intended to include any covalently bonded carriers that release the active parent drug according to Formula I via physiological effects (such as hydrolysis, metabolism, etc.) in vivo when such prodrugs are administered to an individual. The applicability and technology involved in preparing and using prodrugs are well known to those of ordinary skill in the art. The prodrug of the compound (parent compound) of formula (I) can be prepared by modifying the functional groups present in the compound in such a way that the variant is cracked into the parent compound in conventional operation or in vivo. "Prodrug" includes compounds of formula (I) in which hydroxyl, amine or sulfhydryl groups are bonded to any group, and when the prodrug is administered to an individual, the group is cracked to form free hydroxyl, free amine or free sulfhydryl groups respectively. Examples of prodrugs include, but are not limited to, derivatives and metabolites of the compound of formula (I), which include biohydrolyzable moieties, such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides and biohydrolyzable phosphate analogs. In a particular embodiment, the prodrug of a compound of formula (I) having a carboxyl functional group is a lower alkyl (eg C1-C6) ester of a carboxylic acid. Carboxylic acid esters are conveniently formed by esterifying any carboxylic acid moiety present on the molecule.
[0045] As used herein, the term "solvate" means a compound or a pharmaceutically acceptable salt thereof that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. If the solvent is water, the solvate may be conveniently referred to as a "hydrate," such as a hemihydrate, monohydrate, sesquihydrate, dihydrate, trihydrate, etc.
[0046] As used herein, the term "Myt1 inhibitor" refers to a compound that, upon exposure to the enzyme Myt1 (whether in vitro, in cell culture, or in an animal), reduces Myt1 activity such that a measured Myt1 IC50 is 10 mM or less (e.g., 5 mM or less or 1 mM or less).
[0047] For certain Myt1 inhibitors, the Myt1 IC50 may be 100 nM or less (e.g., 10 nM or less, or 3 nM or less) and may be as low as 100 pM or 10 pM. Preferably, the Myt1 IC50 is 1 nM to 1 mM (e.g., 1 nM to 750 nM, 1 nM to 500 nM, or 1 nM to 250 nM).
[0048] Even more preferably, the Myt1 IC50 is less than 20 nm (e.g., 1 nM to 20 nM)
[0049] As used herein, "treatment" refers to the medical management of a subject with the intent to ameliorate, stabilize, prevent, or cure a disease or condition.
[0050] The term includes active treatment (treatment intended to improve the disease or condition); causal treatment (treatment directed at the cause of the disease or condition in question); palliative care (treatment intended to relieve the symptoms of the disease or condition in question); preventive treatment (treatment intended to reduce or partially or completely arrest the progression of the disease or condition in question); and supportive care (treatment used to supplement another treatment).
[0051] Compound
[0052] The present invention provides a compound of formula (I):
[0053] in:
[0054] Ring A is indazolyl;
[0055] R is halogen, hydroxy, oxo, cyano, nitro, amine, alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -B(OH)2, -S(=O)-alkyl, -S(=O)2-alkyl, -S(=O)NH2, -S(=O)2NH2, -P(=O)-dialkyl, -C(=O)NH2, -C(=O)alkyl, -C(=O)alkoxy, boronic acid, heterocyclyl, aryl or heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with a group selected from the group consisting of halogen, hydroxy, amine, alkyl, aryl, heteroaryl or heterocyclyl;
[0056] Z1 is a direct key;
[0057] Z2, Z3 and Z4 are independently CR a or N;
[0058] Z5 is -C(=O)-, N or CR a , where R a is hydrogen, alkyl, hydroxyalkyl, alkenyl, alkynyl, amino or cyano;
[0059] Z6 and Z7 are independently CR a or N;
[0060] wherein the position of the double bond on the bicyclic ring to which ring A is attached changes with Z2 to Z7 being N or -C(=O)-; and wherein R a is hydrogen, alkyl, hydroxyalkyl, alkenyl, alkynyl, amino or cyano;
[0061] X is -C(=O)- or NR c , where R c is a heterocyclic group, an aryl group, or a heteroaryl group; wherein the heterocyclic group, the aryl group, or the heteroaryl group is optionally substituted by a group selected from the group consisting of a hydroxyl group, an amine group, an alkyl group, an aryl group, a heteroaryl group, or a heterocyclic group;
[0062] R2, R3 and R4 are independently hydrogen, alkyl, -C(=O)NH2, amine, alkylamino or dialkylamino; wherein the alkyl, amine, alkylamino or dialkylamino is optionally substituted with a group selected from the group consisting of hydroxy, amine, alkyl, aryl, heteroaryl or heterocyclyl;
[0063] R5 is alkyl, amino, alkylamino or dialkylamino; wherein the alkyl, amino, alkylamino or dialkylamino is optionally substituted by a group selected from the group consisting of hydroxy, amino, alkyl, aryl, heteroaryl or heterocyclyl; and R5 and R4 together form a 5- to 8-membered heteroaromatic or heterocyclic ring; wherein the heteroaromatic or heterocyclic ring is optionally substituted by a group selected from the group consisting of halogen, cyano, alkoxy, carbonyl, hydroxy, amino, alkyl, aryl, heteroaryl, heterocyclyl or cycloalkyl;
[0064] R6 is hydrogen, amine, alkylamino or dialkylamino; or, R6 and the Z3 to which it is attached together form -C(=O)-;
[0065] n is 3 or 4;
[0066] or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof.
[0067] The present invention also provides a compound of formula (IC):
[0068] in:
[0069] Ring A is indazolyl;
[0070] each R1 is independently halogen, hydroxy, oxo, cyano, nitro, amine, alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -B(OH)2, -S(=O)-alkyl, -S(=O)2-alkyl, -S(=O)NH2, -S(=O)2NH2, -P(=O)-dialkyl, -C(=O)NH2, -C(=O)alkyl, -C(=O)alkoxy, boronic acid, heterocyclyl, aryl or heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with a group selected from the group consisting of halogen, hydroxy, amine, alkyl, aryl, heteroaryl or heterocyclyl;
[0071] n is 3 or 4;
[0072] X is -C(=O)- or NR c , where R c is a heterocyclic group, an aryl group or a heteroaryl group;
[0073] R5 is an alkyl group, an amino group, an alkylamino group or a dialkylamino group; wherein the alkyl group, the amino group, the alkylamino group or the dialkylamino group is optionally substituted by a group selected from the group consisting of a hydroxyl group, an amino group, an alkyl group, an aryl group, a heteroaryl group or a heterocyclic group;
[0074] Ring B and Ring C may exist simultaneously or not;
[0075] Ring B is a 5- to 8-membered heteroaromatic or heterocyclic ring; wherein the heteroaromatic or heterocyclic ring is optionally substituted by a group selected from the group consisting of halogen, cyano, alkoxy, carbonyl, hydroxy, amine, alkyl, aryl, heteroaryl, heterocyclyl, or cycloalkyl; and
[0076] Ring C is a 5- to 8-membered heteroaromatic or heterocyclic ring; wherein the heteroaromatic or heterocyclic ring is optionally substituted by a group selected from the group consisting of halogen, cyano, alkoxy, carbonyl, hydroxy, amino, alkyl, aryl, heteroaryl, heterocyclyl, or cycloalkyl;
[0077] or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof.
[0078] In one embodiment, the compound of formula (I) is a compound of formula (IC).
[0079] In one embodiment of the compound of Formula (I) or Formula (IC), X is -C(=O)-.
[0080] In another embodiment of the compound of Formula (I) or Formula (IC), X is NR c , where R c is a heterocyclic group, an aryl group or a heteroaryl group.
[0081] In one embodiment of the compound of formula (I) or formula (IC), R1 is selected from the group consisting of:
[0082] -CH3, -CN, -OH, -OCH3, -F, -Cl, -Br, -CF3, -CCl3, -NO2, -B(OH)2,
[0083] In one embodiment of the compound of formula (I) or formula (IC), Z1 is a direct bond; Z3 is C; at least one of Z2 and Z4 is N; Z5 is -C(=O)-, N or CR a , where R a is hydrogen, alkyl, hydroxyalkyl, alkenyl, alkynyl, amino or cyano; Z6 and Z7 are independently C or N.
[0084] In one embodiment of the compound of formula (I) or formula (IC), R2, R3 and R4 are independently hydrogen, alkyl, -C(=O)NH2 or amine; R5 is alkyl or amine; and R6 is hydrogen or amine.
[0085] In one embodiment of the compound of formula (IC), R5 is alkyl or amine.
[0086] In one embodiment, in the compound of formula (IA), Ring A is indazolyl; each R1 is independently hydrogen, halogen, hydroxy, cyano, nitro, amino, unsubstituted alkyl, alkyl substituted with hydroxy, alkoxy, alkylamino, haloalkyl, -S(=O)-alkyl, -S(=O)2-alkyl, -S(=O)NH2, -S(=O)2NH2, -P(=O)-dialkyl, -C(=O)NH2, -C(=O)alkyl, -C(=O)alkoxy, or boronic acid; and n is 3 or 4.
[0087] In one embodiment, in the compound of formula (IC), X is -C(=O)-; R5 is alkyl or amine; Ring B is a 6-membered or 7-membered heteroaromatic or heterocyclic ring; wherein the heteroaromatic or heterocyclic ring is optionally substituted with a group selected from the group consisting of halogen, cyano, alkoxy, carbonyl, hydroxy, amine, alkyl, aryl, heteroaryl, heterocyclyl, or cycloalkyl; and Ring C is absent.
[0088] In yet another embodiment of the compounds of Formula (I) or Formula (IC), Ring A is indazolyl; X is -C(=O)-; and R1 is selected from the group consisting of: -CH3, -CN, -OH, -OCH3, -F, -Cl, -Br, -CF3, -CCl3, -NO2, -B(OH)2,
[0089] In another preferred embodiment, the present invention provides a compound of formula (I) selected from the following:
[0090] The present invention also provides a compound of formula (II):
[0091] in:
[0092] Ring A is indazolyl;
[0093] R1 is halogen, hydroxy, oxo, cyano, nitro, amino, alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -S(=O)-alkyl, -S(=O)2-alkyl, -S(=O)NH2, -S(=O)2NH2, -P(=O)-dialkyl, -C(=O)NH2, -C(=O)alkyl, -C(=O)alkoxy, boronic acid, heterocyclyl, aryl or heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with a group selected from the group consisting of hydroxy, amino, alkyl, aryl, heteroaryl or heterocyclyl;
[0094] n is 3 or 4;
[0095] or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof.
[0096] The compound of formula (II) is a starting compound for the preparation of the compound of formula (I).
[0097] In yet another embodiment of the compound of formula (II), Ring A is indazolyl; R1 is selected from the group consisting of:
[0098] -CH3, -CN, -OH, -OCH3, -F, -Cl, -Br, -CF3, -CCl3, -NO2, -B(OH)2,
[0099] And n is 3 or 4.
[0100] In another preferred embodiment, the present invention provides a compound of formula (II) selected from the following:
[0101] Pharmaceutical compositions, uses and methods
[0102] The compounds of the present invention can be administered therapeutically as pure chemicals, but it may be appropriate to administer the compounds as pharmaceutical compositions or formulations. Accordingly, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof and one or more pharmaceutically acceptable carriers or excipients.
[0103] The pharmaceutical composition can be administered in various dosage forms, including but not limited to solid or liquid dosage forms, oral dosage forms, parenteral dosage forms, intranasal dosage forms, suppositories, lozenges, dragees, oral, controlled release dosage forms, pulsed release dosage forms, immediate release dosage forms, intravenous solutions, suspensions, or combinations thereof. The compound can be administered, for example, orally or parenterally, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, respiratory (aerosol), rectal, vaginal, and topical (including oral and sublingual) administration.
[0104] In one embodiment of the present invention, the compound of formula (I) is administered orally. For oral administration, the compound will generally be provided as a unit dosage form suitable for ingestion by an individual, such as tablets, pills, dragees, lozenges, or capsules; as a powder or granules; or as an aqueous solution, suspension, liquid, gel, syrup, slurry, or the like. The dosage form may be a tablet or a controlled release formulation of a tablet. Tablets for oral use may include the active ingredient mixed with one or more pharmaceutically acceptable excipients.
[0105] "Excipient" generally refers to a substance added to a pharmacological composition or used as a vehicle to further assist in the administration of a compound, typically an inert substance. Examples of excipients include, but are not limited to, inert diluents, disintegrating agents, binders, lubricants, sweeteners, flavorings, colorants, preservatives, foaming mixtures, and adsorbents. Suitable inert diluents include, but are not limited to, sodium carbonate and calcium carbonate, sodium phosphate and calcium phosphate, lactose, and the like. Suitable disintegrating agents include, but are not limited to, starch (such as corn starch), cross-linked polyvinyl pyrrolidone, agar, alginic acid or its salts (such as sodium alginate), and the like. Binders may include, but are not limited to, magnesium aluminum silicate, starch (such as corn, wheat, or rice starch), gelatin, methylcellulose, sodium carboxymethylcellulose, polyvinyl pyrrolidone, and the like. If present, lubricants are typically magnesium stearate and calcium stearate, stearic acid, talc, or hydrogenated vegetable oil. If desired, tablets may be coated with materials such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract. The composition can also be formulated as a chewable tablet, for example, by using substances such as mannitol in the formulation.
[0106] Pharmaceutical compositions for oral use can be obtained by combining a compound of formula (I) with a solid excipient, optionally grinding the resulting mixture, and processing the mixture granules after adding suitable other compounds (if desired) to obtain tablets or dragee cores. Suitable solid excipients include, in addition to those mentioned previously, carbohydrate or protein fillers, including but not limited to: sugars, including lactose, sucrose, mannitol or sorbitol; starch from corn, wheat, rice, potato or other plants; cellulose, such as methylcellulose, hydroxypropyl methylcellulose or sodium carboxymethylcellulose; and gums, including gum arabic and tragacanth; and proteins, such as gelatin and collagen.
[0107] Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent and soft gelatin capsules in which the active ingredient is mixed with water or oil (such as peanut oil, liquid paraffin or olive oil).
[0108] Dragee cores are provided with a suitable coating. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol and / or titanium dioxide, lacquers and suitable organic solvents or solvent mixtures. Dyes or pigments may be added to the tablets or dragee coatings to identify or characterize different combinations of active compound doses.
[0109] The pharmaceutical composition may also contain a suitable solid or gel phase carrier. Examples of such carriers include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycol.
[0110] Compounds and pharmaceutical compositions suitable for use in the present invention include those in which the active ingredient is administered in an amount effective to achieve its intended purpose. The term "therapeutically effective amount" refers to an amount of a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof, alone or in combination with ionizing radiation or an anticancer agent, that provides the desired effect in the individual being treated when administered a single or multiple doses to the individual. The toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as determining the IC 50 As used herein, “IC 50 ” refers to the concentration of the drug that may produce 50% of the maximum inhibitory reaction.
[0111] The actual amount of the compound of formula (I) administered will be determined by the physician under relevant circumstances, including the condition to be treated, the size and type of neoplasia, the route of administration selected, the actual compound of the invention administered, the timing of administration of the hedgehog pathway modulator relative to other therapies, the type, species, age, weight, sex and medical condition of the individual, the individual's renal and liver function, and the severity of the individual's symptoms. Achieving optimal precision in producing drug concentrations within the efficacy range requires a regimen based on the kinetics of the drug's availability to the target site. This involves considering the distribution, equilibrium, and elimination of the drug. In some cases, dosage levels below the lower limit of the aforementioned range may be more than adequate, while in other cases still larger doses may be employed.
[0112] A "subject" to be treated by the methods of the present invention means a human or non-human animal, such as a primate, mammal, and vertebrate.
[0113] "In vivo" means within a living individual, such as an animal or human. As used herein, an agent can be used therapeutically in vivo to slow or eliminate the proliferation of abnormal replicating cells. An agent can also be used in vivo as a prophylactic agent to prevent the manifestation of abnormal cell proliferation or symptoms associated therewith.
[0114] "In vitro" means outside a living individual. Examples of in vitro cell populations include cell cultures and biological samples, such as fluid or tissue samples from humans or animals. Such samples can be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. As used herein, the compounds of the present invention can be used in a variety of therapeutic and experimental applications.
[0115] The present invention also relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof for the manufacture of a medicament for modulating the Hedgehog pathway.
[0116] Furthermore, the present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof.
[0117] "Cancer" refers to a cell proliferative disorder including, but not limited to, cardiac cancers such as sarcomas (e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma), myxoma, rhabdomyomas, fibromas, lipomas, and teratomas; lung cancers such as bronchogenic carcinomas (e.g., squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, and adenocarcinoma), alveolar carcinomas (e.g., bronchiolar carcinoma), bronchial adenomas, sarcomas, lymphomas, cartilaginous hamartomas, and mesotheliomas; gastrointestinal cancers such as esophageal cancer (e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma), gastric cancer (e.g., lymphoma and leiomyosarcoma), pancreatic cancer (e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid, and vipoma), small intestinal cancer (e.g., adenocarcinoma, lymphoma, carcinoid, Kaposi's sarcoma, sarcoma), leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma); colorectal cancer (e.g., adenocarcinoma, ductal adenoma, villous adenoma, hamartoma, and leiomyomas); genitourinary tract cancers, such as kidney cancer (e.g., adenocarcinoma, Wilms' tumor, lymphoma, and leukemia); bladder and urethral cancer (e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma); prostate cancer (e.g., adenocarcinoma and sarcoma), testicular cancer (e.g., spermatoma, teratoma, embryonal tumor, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, and lipoma); liver cancer, such as hepatocellular carcinoma (e.g., hepatocellular carcinoma), bile duct cancer, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma; bone cancer, such as osteogenic sarcoma (e.g., osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, sarcoma), malignant lymphoma (e.g., reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (e.g., osteochondral exostoses), benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor; nervous system cancers, such as skull cancer (e.g., osteoma, hemangioma, granuloma, xanthomas, and osteitis malformation), meningeal cancer (e.g., meningioma, meningeal sarcoma, and gliosis), brain cancer (e.g., astrocytoma, medulloblastoma, glioma, ependymoma, blastoma (pinealoma), glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors), spinal neurofibroma, meningioma, glioma, and sarcoma;Gynecological cancers, such as uterine cancer (e.g., endometrial cancer), cervical cancer (e.g., cervical cancer and preneoplastic cervical dysplasia), ovarian cancer (e.g., ovarian cancer [e.g., serous cystadenocarcinoma, mucinous cystadenocarcinoma, and unclassified carcinoma], granulosa cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, and malignant teratoma), vulvar cancer (e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma), vaginal cancer (e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma [e.g., embryonal rhabdomyosarcoma], and fallopian tube cancer); hematological cancers, such as hematological cancers (myeloid leukemias [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, and myelodysplasia), Hodgkin's disease ( disease), non-Hodgkin's lymphoma [malignant lymphoma]; skin cancers such as malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; adrenal gland cancers such as neuroblastoma; or breast cancer.
[0118] The compounds of formula (I) may be administered as the sole active pharmaceutical agent or in combination with other known cancer treatments.
[0119] The term "and together" means that the compound of formula (I) can be administered shortly before, shortly after, simultaneously, or any combination of shortly before, shortly after, or simultaneously with one or more other anti-tumor therapies. Thus, the compound of formula (I) and the second anticancer agent can be administered as a single composition or as two separate compositions simultaneously or as two separate compositions sequentially. Similarly, the compound of formula (I) and chemotherapy or ionizing radiation therapy can be administered simultaneously, separately, or sequentially. It will be understood by those skilled in the art that the amount of the compound of formula (I) administered in conjunction with the anticancer therapy is preferably an amount sufficient to enhance the effect of the anticancer therapy or an amount sufficient to induce apoptosis or cell death together with the anticancer therapy to maintain an anti-angiogenic effect.
[0120] Unless otherwise specified, the term "second anticancer agent" as used herein refers to an agent that can inhibit or prevent the growth of a tumor or detect the maturation and proliferation of malignant (cancer) cells. Second anticancer agents suitable for use in combination with a compound of formula (I) include, but are not limited to, targeted cancer drugs,Such as trastuzumab, ramucirumab, bevacizumab, everolimus, tamoxifen, toremifene, fulvestrant, anastrozole, exemestane, lapatinib, letrozole, pertuzumab, ado-trastuzumab, and mabemtansine), palbociclib, cetuximab, panitumumab, ziv-aflibercept, regorafenib, lmatinib mesylate, lanreotide acetate, sunitinib, regorafenib, denosumab, alitretinoin, Sorafenib, pazopanib, temsirolimus, everolimus, tretinoin, dasatinib, nilotinib, bosutinib, rituximab, alemtuzumab, ofatumumab, obinutuxumab, ibrutinib, idelali sib), blinatumomab, soragenib, crizotinib, erlotinib, gefitinib, afatinib dimaleate, ceritnib, ramucirumab, nivolumab, pembrolizumab, osimertinib, and necitumumab; alkylating agents,Such as busulfan, chlorambucil, cyclophosphamide, ifosfamide, melphalan, mechlorethamine, streptozotocin, thiotepa, uracil mustard, triethylenemelamine, temozolomide, and 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU); antibiotics or plant alkaloids, such as actinomycin-D, bleomycin, scintipramine, daunorubicin, doxorubicin, idarubicin, irinotecan, L-asparaginase, mitomycin-C, mitramycin, navelbine, paclitaxel, docetaxel, topotecan, vinblastine vinblastine, vincristine, teniposide (VM-26), and etoposide (VP-16); hormones or steroids, such as 5-alpha-reductase inhibitors, aminoglutethimide, anastrozole, bicalutamide, chlorotriarylethylene, diethylstilbestrol (DES), dromostanolone, estramustine, ethinyl estradiol, flutamide, fluoxymesterone, goserelin, hydroxyprogesterone, letrozole, leuprolide, medroxyprogesterone acetate acetate), megestrol acetate, methylprednisolone, methyltestosterone, mitotane, nilutamide, prednisolone, arzoxifene (SERM-3), tamoxifen, testolactone, testosterone, triamicnolone, and Zoladex; synthetic preparations,Such as all-trans retinoic acid, carmustine (BCNU), carboplatin (CBDCA), lomustine (CCNU), cis-diamminedichloroplatinum (cisplatin), dacarbazine, gliadel, hexamethylmelamine, hydroxyurea, levamisole, mitoxantrone, o,p'-dichlorodiphenyldichloroethane (o,p'-DDD) (also known as lysodren or mitotane), oxaliplatin, porfimer sodium, procarbazine, and imatinib mesylate, antimetabolites, such as chlorodeoxyadenosine, cytosine arabinoside, 2'-deoxycoformycin, fludarabine phosphate, 5-fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (5-FUdR), gemcitabine, camptothecin, 6-mercaptopurine, methotrexate, and thioguanine; and biologics, such as interferon alpha, Bacillus Calmette-Guerin (BCG), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and herceptin.
[0121] Unless otherwise specified, the term "treating" as used herein means reversing, alleviating, inhibiting the development of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. Unless otherwise specified, the term "treatment" as used herein refers to the act of treating as "treating" is defined above.
[0122] Compound synthesis
[0123] The present invention also relates to a method for preparing a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof. The compounds of the present invention can be prepared by a person skilled in the art using conventional organic synthesis methods and commercially available materials.
[0124] In one embodiment, the method for preparing a compound of formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof comprises:
[0125] a. Make the compound of formula (II)
[0126] and pyridine of formula (III)
[0127] Reaction in the presence of a catalyst to obtain a compound of formula (IV)
[0128] wherein Ring A, R1 and n are as defined herein, Hal is halogen; R A is an alkyl group;
[0129] b. reacting a compound of formula (IV) with a coupling agent containing a cyano group to obtain a compound of formula (I')
[0130] c. subjecting the compound of formula (I') to an acylation reaction in the presence of an acid to obtain a compound of formula (I)
[0131] By way of illustration and not intended to be limiting, a general synthetic route for a representative compound of Formula (I) or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof is shown in Scheme 1. It should be noted that one skilled in the art can modify the steps described in the illustrative schemes and examples to obtain the desired product.
[0132] Process 1
[0133] Examples
[0134] Example 1:
[0135] Synthesis of compound 126
[0136] Step 1
[0137] To a solution of compound 126-1 (50 g, 236.90 mmol) and 3,4-dihydro-2H-pyran (43.32 mL, 473.80 mmol, Anaiji) in dichloromethane (400 mL) was added p-toluenesulfonic acid hydrate (4.51 g, 23.69 mmol), and the resulting mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 20:1 to 10:1) to obtain compound 126-2 (68.4 g, 231.72 mmol, yield = 98%) as a yellow solid. LC-MS (ESI): m / z = 295.0 / 297.0 [M+H] + .
[0138] Step 2
[0139] To a mixed solution of compound 126-2 (40 g, 135.51 mmol), benzylamine (15.56 mL, 142.29 mmol), sodium tert-butoxide (26.05 g, 271.02 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (4.70 g, 8.13 mmol), and toluene (400 mL) was added tris(dibenzylideneacetone)dipalladium (3.72 g, 4.07 mmol). The mixture was degassed and replaced with nitrogen three times and stirred at 105°C for 18 hours. The reaction solution was concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether:ethyl acetate = 10:1 to 3:1) to obtain compound 126-3 (39.8 g, 123.83 mmol, yield = 91%) as a yellow solid. LC-MS (ESI): m / z = 322.2 [M+H] + .
[0140] Step 3
[0141] To a mixed solution of compound 126-3 (21.1 g, 65.65 mmol) in methanol (200 mL) and acetic acid (0.5 mL) was added palladium on carbon (3.49 g, 3.28 mmol). The mixture was degassed and replaced with hydrogen three times, and stirred at room temperature for 18 hours. The mixture was filtered, and the filter cake was washed three times with methanol (200 mL). The filtrate was concentrated to dryness to obtain compound 126-4 (15.46 g, 63.50 mmol, yield = 97%) as a gray solid. LC-MS (ESI): m / z = 232.1 [M+H] + .
[0142] Step 4
[0143] To a mixed solution of compound 126-4 (2.00 g, 7.55 mmol), compound 126-4.1 (1.75 g, 7.55 mmol), cesium carbonate (6.15 g, 18.87 mmol), and ethylene glycol dimethyl ether (40 mL) were added tris(dibenzylideneacetone)dipalladium (0.69 g, 0.75 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.87 g, 1.51 mmol), respectively. The reaction solution was purged with nitrogen three times and stirred at 90°C for 18 hours. The reaction solution was concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether:ethyl acetate = 20:1 to 10:1) to obtain compound 126-5 (2.16 g, 5.20 mmol, yield = 68.9%) as a yellow solid. LC-MS(ESI): m / z=415.2 / 417.2[M+H] + .
[0144] Step 5
[0145] To a mixed solution of compound 126-5 (2.16 g, 5.20 mmol), malononitrile (1.03 g, 15.60 mmol, Bid) and ethylene glycol dimethyl ether (40 mL) were added 1,1-bis(diphenylphosphino)dibenzoylmethane palladium chloride (0.38 g, 0.52 mmol) and sodium tert-butoxide (1.25 g, 13.00 mmol), respectively. The reaction solution was purged with nitrogen three times and stirred at 100°C for 18 hours. The reaction solution was concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: ethyl acetate: petroleum ether = 30-40%) to obtain compound 126-6 (1.93 g, 4.82 mmol, yield = 92.7%) as a yellow solid. LC-MS (ESI): m / z = 401.2 [M+H] + .
[0146] Step 6
[0147] To a solution of compound 126-6 (900 mg, 2.25 mmol) in acetic acid (18 mL) was added liquid bromine (230.95 μL, 4.49 mmol), and the mixture was stirred at 45°C for 2 hours. The mixture was poured into water (50 mL) and extracted three times with ethyl acetate (30 mL), washed with brine (50 mL), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was purified by reverse phase preparation (eluent: water: acetonitrile = 3:2) to obtain compound 126-7 (330 mg, 0.83 mmol, yield = 37.1%) as a yellow solid. LC-MS (ESI): m / z = 395.2 / 397.2 [M+H] + .
[0148] Step 7
[0149] To a solution of compound 126-7 (120 mg, 0.30 mmol) in methanesulfonic acid (2 mL) were added water (180 μL, 9.99 mmol) and concentrated sulfuric acid (90 μL, 1.70 mmol), and the mixture was stirred at 50°C for 18 hours. The mixture was adjusted to pH 8 with sodium hydroxide solution (1 M) and extracted three times with ethyl acetate (10 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain the crude product. The crude product was purified by reverse phase preparation (eluent: 30% to 40% (v / v) acetonitrile and water containing 0.1% trifluoroacetic acid) to obtain compound 126-8 (70 mg, 0.17 mmol, yield = 55.8%) as a yellow solid. LC-MS (ESI): m / z = 413.2 / 415.2 [M+H] + .
[0150] Step 8
[0151] To a mixed solution of compound 126-8 (70 mg, 0.17 mmol), compound 126-9 (53.53 μL, 0.26 mmol), 1,4-dioxane (2 mL), and water (0.5 mL) were added potassium carbonate (70 mg, 0.51 mmol), tricyclohexylphosphine (9.5 mg, 0.03 mmol), and tris(dibenzylideneacetone)dipalladium (15.5 mg, 0.02 mmol). The mixture was stirred at 100°C under nitrogen for 3 hours. Hydrochloric acid (382 μL, 1.53 mmol, 4 M) was then added, and the mixture was stirred at 50°C for 2 hours. The mixture was concentrated to dryness and the crude product was purified by preparative HPLC (Waters-SunFire-C18-10 μm-19*250 mm (eluent: 29% to 59% (v / v) acetonitrile and water containing 10 mM ammonium bicarbonate) to afford compound 126 (1.33 mg, 0.003 mmol, yield = 1.9%) as a white solid. LC-MS (ESI): m / z = 359.2 [M+H] + .1H NMR(400MHz, DMSO-d6)δ:13.24(s,1H),8.27(d,J=7.0Hz,1H),7.63(d,J=8.6Hz,1H),7.52(d,J=1.0Hz,1H),7.41(d,J= 8.6Hz,1H),6.47(s,2H),5.64(dd,J=10.6,7.2Hz,1H),5.24(d,J=10.2Hz,1H),2.08(s,3H),2.04(s,3H),1.98(s,3H).
[0152] Example 2:
[0153] Synthesis of compound 136
[0154] Step 1
[0155] To a solution of compound 136-1 (5 g, 23.25 mmol, Bid) and 3,4-dihydro-2H-pyran (4.25 mL, 46.51 mmol) in dichloromethane (100 mL) was added 4-methylbenzenesulfonic acid hydrate (0.44 g, 2.33 mmol), and the resulting mixture was stirred at 40 ° C for 1.5 hours. The mixture was concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 20: 1 to 10: 1) to obtain a white solid compound 136-2 (6 g, 20.06 mmol, yield = 86.1%). LC-MS (ESI): m / z = 299.0 / 301.0 [M + H] +
[0156] Step 2
[0157] Compound 136-2 (6 g, 20.06 mmol), benzylamine (2.46 mL, 22.46 mmol), sodium tert-butoxide (6.17 g, 64.18 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (19.35 mg, 0.03 mmol) were added to a toluene solution (100 mL), followed by the addition of tris(dibenzylideneacetone)dipalladium (7.65 mg, 0.01 mmol). The mixture was degassed and purged with N2 three times and stirred at 105°C under a N2 environment for 18 hours. The mixture was poured into water (100 mL) and extracted three times with ethyl acetate (100 mL). The combined organic phases were washed with brine (300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10:1 to 2:1) to give compound 136-3 (5.23 g, 16.07 mmol, yield = 75.1%) as a brown solid. LC-MS (ESI): m / z = 326.2 [M+H] +
[0158] Step 3
[0159] To a solution of compound 136-3 (5.23 g, 16.07 mmol) in methanol (100 mL) was added wet Pd / C (0.84 mL, 10%, 0.80 mmol), the mixture was degassed and replaced with hydrogen three times, and stirred at 25 ° C for 3 days. The suspension was filtered through celite, washed with methanol (100 mL), and the filtrate was concentrated to dryness. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10: 1 to 6: 4) to give compound 136-4 (3.22 g, 13.69 mmol, yield = 85.1%) as a yellow oil. LC-MS (ESI): m / z = 236.2 [M + H] +
[0160] Step 4
[0161] To a solution of compound 136-4 (3.22 g, 13.69 mmol) in dichloromethane (50 mL) was added N-chlorosuccinimide (2.01 g, 15.06 mmol) and stirred at 0°C for 1 hour. The mixture was poured into water (20 mL) and extracted three times with dichloromethane (30 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10:1 to 5:1) to obtain compound 136-5 (3.65 g, 13.53 mmol, yield = 98.8%) as a yellow solid. LC-MS (ESI): m / z = 270.1 [M+H] +
[0162] Step 5
[0163] Compound 136-5 (3.65 g, 13.53 mmol), compound 136-6 (3.59 g, 13.53 mmol) and cesium carbonate (3.04 g, 9.34 mmol) were added to ethylene glycol dimethyl ether (30 mL), and tris(dibenzylideneacetone)dipalladium (0.68 g, 0.74 mmol) and 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (0.86 g, 1.48 mmol) were added respectively. The mixture was degassed and purged with nitrogen three times and stirred at 90°C for 16 hours. The mixture was poured into water (100 mL) and extracted three times with ethyl acetate (100 mL). The combined organic phases were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10:1 to 5:1) to give compound 136-7 (3.5 g, 7.71 mmol, yield = 57.0%) as a yellow solid. LC-MS (ESI): m / z = 453.2 / 455.2 [M+H] +
[0164] Step 6
[0165] Compound 136-7 (3.5 g, 7.71 mmol), malononitrile (2.04 g, 30.85 mmol, Bid), sodium tert-butoxide (2.22 g, 23.14 mmol) and ethylene glycol dimethyl ether (25 mL) were added to a 40 mL microwave tube. The resulting mixture was purged with nitrogen for 5 minutes, and then 1'-bis(diphenylphosphino)ferrocene]dichloropalladium (1.13 g, 1.54 mmol) was added, and the resulting mixture was stirred at 120°C in a microwave for 1.5 hours. The mixture was poured into water (100 mL) and extracted three times with ethyl acetate (50 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10:1 to 1:1) to give compound 136-8 (1700 mg, 3.87 mmol, yield = 50.2%) as a yellow oil. LC-MS (ESI): m / z = 439.2 [M+H] +
[0166] Step 7
[0167] Liquid bromine (117.08 μL, 2.28 mmol) was added to a mixed solution of compound 136-8 (900 mg, 2.25 mmol) and acetic acid (4 mL) and stirred at 45°C for 2 hours. The mixture was poured into water (20 mL) and extracted three times with ethyl acetate (30 mL). The combined organic phases were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by preparative HPLC (Phenomenex Gemini 150 mm*25 mm*10 μm column (eluent: 30% to 60% (v / v) acetonitrile and water containing 0.025% formic acid) to obtain compound 136-9 (150 mg, 0.35 mmol, yield = 15.8%) as a yellow solid. LC-MS (ESI): m / z = 433.0 / 435.0 [M+H] +
[0168] Step 8
[0169] Compound 136-9 (102 mg, 0.24 mmol) was added to a solution of methanesulfonic acid (2 mL), followed by concentrated sulfuric acid (137.90 μL, 2.59 mmol) and water (55.10 μL, 3.06 mmol), respectively. The reaction was stirred at 50°C for 18 hours. The mixture was quenched with saturated sodium bicarbonate solution (40 mL) and extracted three times with ethyl acetate (30 mL). The combined organic phases were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain the crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether:ethyl acetate = 10:1 to 0:1) to obtain compound 136-10 (45 mg, 0.10 mmol, yield = 42.4%) as a yellow oil. LC-MS (ESI): m / z = 451.0 / 453.0 [M+H] +
[0170] Step 9
[0171] Compound 136-10 (35 mg, 0.08 mmol) and 2-[(1E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (32.83 μL, 0.15 mmol, Bid) were added to a dioxane (1 mL) solution. Tris(dibenzylideneacetone)dipalladium (0.87 mg, 0.01 mmol, Bid), dicyclohexyl[2-(2,6-dimethoxyphenyl)phenyl]phosphine (3.18 mg, 0.01 mmol, Bid), and potassium carbonate (32.90 mg, 0.15 mmol) were then added. The mixture was stirred at 95°C under nitrogen for 18 hours. Dilute HCl (2 mL, 6 mol / L) was then added, and the mixture was stirred at 25°C for 3 hours. The mixture was poured into a saturated aqueous sodium bicarbonate solution (20 mL) and extracted three times with ethyl acetate (30 mL). The combined organic phases were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give a crude product. The crude product was purified by preparative HPLC (Phenomenex Gemini 150 mm*25 mm*10 μm column (eluent: 30% to 60% (v / v) acetonitrile and water containing 0.025% formic acid) to give Compound 136 (1 mg, 0.001 mmol, yield = 3.25%) as a white solid. LC-MS (ESI): m / z = 396.9 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ:14.10(s,1H),8.35–8.26(m,1H),7.98–7.81(m,1H),7.71–7.63( m,1H),6.71(s,2H),5.73–5.58(m,1H),5.26(d,J=10.4Hz,1H),2.11(s,3H),2.00(s,3H).
[0172] Example 3:
[0173] Synthesis of compound 137
[0174] Step 1
[0175] To a solution of compound 137-1 (2.2 g, 11.61 mmol, Bid) in trifluoroacetic acid (11 mL) and concentrated sulfuric acid (2.75 mL) was added N-bromosuccinimide (3.10 g, 17.41 mmol) and stirred at 40° C. for 18 hours. TLC showed that the starting material had been completely consumed, and less polar spots were observed. The reaction mixture was poured into (50 mL) of water and extracted three times with (30 mL) of ethyl acetate. The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: 100% petroleum ether) to obtain compound 137-2 (2.8 g, 10.43 mmol, yield = 90%) as a green oil.
[0176] Step 2
[0177] To a mixed solution of compound 137-2 (2.8 g, 10.43 mmol), ethanol (50 mL), and water (10 mL) were added iron powder (2.33 g, 41.72 mmol) and ammonium chloride (1.67 g, 31.29 mmol), respectively, and the resulting mixture was stirred at 80°C for 2 hours. The mixture was filtered, the filter cake was washed three times with methanol (30 mL), and the filtrate was concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10:1 to 4:1) to obtain compound 137-3 (2.56 g, 10.41 mmol, yield = 99%) as a yellow oil. LC-MS (ESI): m / z = 238.0 / 240.0 [M+H] + .
[0178] Step 3
[0179] To a solution of compound 137-3 (2.06 g, 8.64 mmol) in acetic acid (20 mL) was added sodium nitrite (2.38 g, 34.55 mmol) at 0°C and stirred at room temperature for 18 hours. The mixture was poured into water (50 mL) and extracted three times with ethyl acetate (50 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10: 1 to 4: 1) to give compound 137-4 (1 g, 4.01 mmol, yield = 45%) as a yellow solid. LC-MS (ESI): m / z = 249.0 / 251.0 [M+H] + .
[0180] Step 4
[0181] To a solution of compound 137-4 (1.0 g, 4.01 mmol) and 3,4-dihydro-2H-pyran (0.73 mL, 8.02 mmol) in dichloromethane (2 mL) was added p-toluenesulfonic acid hydrate (76.25 mg, 0.40 mmol), and the resulting mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10: 1 to 5: 1) to obtain compound 137-5 (868 mg, 2.60 mmol, yield = 64%) as a yellow solid. LC-MS (ESI): m / z = 333.0 / 335.0 [M+H] + .
[0182] Step 5
[0183] To a solution of compound 137-5 (800 mg, 2.40 mmol) and compound 137-5.1 (337.54 mg, 1.68 mmol) in ethylene glycol dimethyl ether (16 mL) were added tris(dibenzylideneacetone)dipalladium (219.61 mg, 0.24 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (277.53 mg, 0.48 mmol), and cesium carbonate (1953.42 mg, 6.00 mmol), respectively. The mixture was purged with nitrogen three times and stirred under nitrogen at 100°C for 3 hours. The mixture was poured into water (50 mL) and extracted three times with ethyl acetate (30 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10:1 to 4:1) to give compound 137-6 (480 mg, 1.06 mmol, yield = 44%) as a yellow solid. LC-MS (ESI): m / z = 453.2 / 455.2 [M+H] + .
[0184] Step 6
[0185] To a solution of compound 137-6 (480 mg, 1.06 mmol) and malononitrile (209.65 mg, 3.17 mmol, Bid) in ethylene glycol dimethyl ether (9 mL) were added 1,1-bis(diphenylphosphino)dibenzoylmethane palladium chloride (77.4 mg, 0.10 mmol) and sodium tert-butoxide (254.15 mg, 2.65 mmol). The mixture was purged with nitrogen three times and stirred at 120°C under nitrogen for 48 hours. The mixture was poured into water (40 mL) and extracted three times with ethyl acetate (30 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain the crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether:ethyl acetate = 10:1 to 3:2) to obtain compound 137-7 (300 mg, 0.68 mmol, yield = 65%) as a yellow solid. LC-MS (ESI): m / z = 439.2 [M+H] + .
[0186] Step 7
[0187] To a solution of compound 137-7 (300 mg, 0.68 mmol) in acetic acid (2 mL) was added liquid bromine (23.42 μL, 0.46 mmol), and the mixture was stirred at room temperature for 2 hours. The mixture was poured into water (20 mL) and extracted three times with ethyl acetate (20 mL). The combined organic phase was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by reverse phase preparation (eluent: 40% to 60% (v / v) acetonitrile and water containing 0.1% trifluoroacetic acid) to obtain compound 137-8 (140 mg, 0.32 mmol, yield = 47%) as a yellow solid. LC-MS (ESI): m / z = 433.0 / 435.0 [M+H] + .
[0188] Step 8
[0189] To a solution of compound 137-8 (140 mg, 0.32 mmol) in methanesulfonic acid (1.4 mL) was added water (220 μL, 12.21 mmol) and concentrated sulfuric acid (110 μL, 2.06 mmol) and stirred at 50 ° C for 18 hours. The reaction mixture was adjusted to pH = 8 with saturated sodium hydroxide solution and extracted three times with ethyl acetate (20 mL). The combined organic phases were washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give a crude product. The crude product was purified by reverse phase preparation (eluent: 40% to 50% (v / v) acetonitrile and water containing 0.1% trifluoroacetic acid) to give compound 137-9 (50 mg, 0.11 mmol, yield = 34%) as a yellow solid. LC-MS (ESI): m / z = 451.0 / 453.0 [M+H] + .
[0190] Step 9
[0191] To a solution of compound 137-9 (40 mg, 0.09 mmol), compound 137-9.1 (26.31 mg, 0.13 mmol), 1,4-dioxane (2 mL), and water (0.4 mL) were added cesium carbonate (86.56 mg, 0.27 mmol) and tetrakis(triphenylphosphine)palladium (10.24 mg, 0.01 mmol), and the mixture was stirred at 90°C under a nitrogen atmosphere for 2 hours. Hydrochloric acid (6 mL, 1.08 mmol, 4 M) was then added, and the mixture was stirred at 50°C for 2 hours. The mixture was adjusted to pH 7 with 7 M ammonia-methanol solution and concentrated to dryness. The crude product was purified by preparative HPLC (Waters-SunFire-C18-10 μm-19*250 mm (eluent: 37% to 67% (v / v) acetonitrile and water containing 0.1% formic acid) to afford compound 137 (0.76 mg, 0.002 mmol, yield = 2.2%) as a white solid. LC-MS (ESI): m / z = 397.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ: 13.61 (s, 1H), 8.31 (d, J = 7.2Hz, 1H), 7.84 (dd, J = 8.8, 1.2Hz, 1H), 7.74 (d, J = 1 .2Hz,1H),6.77(s,2H),5.65(dd,J=10.6,7.2Hz,1H),5.25(d,J=10.6Hz,1H),2.09(s,3H),1.98(s,3H).
[0192] Example 4:
[0193] Synthesis of compound 138
[0194] Step 1
[0195] To a solution of compound 138-1 (900 mg, 3.61 mmol) in ethylene glycol dimethyl ether (8 mL) were added compound 138-2 (1052.19 mg, 3.97 mmol), cesium carbonate (2940.73 mg, 9.03 mmol), tris(dibenzylidene-BASE acetone)dipalladium (330.60 mg, 0.36 mmol), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (417.80 mg, 0.72 mmol). The mixture was degassed and purged with nitrogen three times and stirred at 90°C for 16 hours. The mixture was concentrated to dryness under reduced pressure to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: ethyl acetate: petroleum ether = 0% to 20%) to obtain compound 138-3 (1.18 g, 2.72 mmol, yield = 75.43%) as a yellow oil. LC-MS(ESI): m / z:433.2 / 435.2[M+H] +
[0196] Step 2
[0197] To a solution of compound 138-3 (300 mg, 0.69 mmol) in ethylene glycol dimethyl ether (5 mL) were added bis[5-(diphenylphosphino)cyclopenta-1,3-dienyl]-λ2-iron(II)palladium chloride (50.66 mg, 0.07 mmol), malononitrile (137.2 mg, 2.08 mmol), and sodium 2-methylpropan-2-ate (166.33 mg, 1.73 mmol), respectively. The mixture was degassed and purged with nitrogen three times, and stirred at 100°C under nitrogen for 16 hours. The mixture was poured into water (4 mL) and extracted three times with ethyl acetate (4 mL). The combined organic phases were washed with brine (4 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 100:1 to 60:40) to give compound 138-4 (525 mg, 0.42 mmol, yield = 60.34%) as a yellow oil. LC-MS (ESI): m / z: 419.2 [M+H] +
[0198] Step 3
[0199] To a solution of compound 138-4 (100 mg, 0.24 mmol) in acetic acid (1 mL) was added liquid bromine (24.56 μL, 0.48 mmol) and stirred at room temperature for 2 hours. The mixture was poured into water (4 mL) and extracted 3 times with ethyl acetate (4 mL). The combined organic phase was washed with brine (4 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure to give a crude product. The crude product was purified by preparative HPLC ((eluent: 0% to 70% (v / v) acetonitrile and water with 0.025% ammonium bicarbonate) to give compound 138-5 (60 mg, 0.15 mmol, yield = 60.76%) as a yellow solid. LC-MS (ESI): m / z: 413.0 / 415.0 [M+H] +
[0200] Step 4
[0201] To a solution of compound 138-5 (40 mg, 0.1 mmol) in methanesulfonic acid (0.5 mL) were added water (61.05 μL, 3.39 mmol) and concentrated sulfuric acid (30.95 μL, 0.58 mmol), respectively, and the mixture was stirred at 50°C for 16 hours. The mixture was adjusted to pH = 7 with sodium hydroxide solution (1 M) and extracted three times with ethyl acetate (3 mL). The combined organic phases were washed with brine (3 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain the crude product. The crude product was purified by preparative TLC (eluent: petroleum ether:ethyl acetate = 1:1) to obtain compound 138-6 (20 mg, 0.05 mmol, yield = 47.92%) as a yellow solid. LC-MS (ESI): m / z: 431.0 / 433.0 [M+H] +
[0202] Step 5
[0203] To a mixed solution of compound 138-6 (20 mg, 0.05 mmol), 2-[(1E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (13.68 μL, 0.06 mmol), tricyclohexylphosphine (1.30 mg, 0.001 mmol), potassium carbonate (19.23 mg, 0.14 mmol), 1,2-dioxane (1 mL) and water (0.2 mL) was added tris[(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one]bis[palladium(0)] (4.25 mg, 0.001 mmol), the mixture was degassed and purged with nitrogen 3 times, and stirred under nitrogen at 90°C for 4 hours. Hydrochloric acid (185.50 μL, 6 M, 0.37 mmol) was then added and stirred at 70°C for 2 hours. The reaction mixture was quenched with saturated sodium bicarbonate solution (2 mL) and extracted three times with ethyl acetate (4 mL). The combined organic phases were washed with brine (3 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to give a crude product. The crude product was purified by preparative HPLC (Phenomenex Gemini 150 mm*25 mm*10 μm column, eluent: 30% to 60% (v / v) acetonitrile and water with 0.025% ammonium bicarbonate) to give compound 138 (1 mg, 0.002 mmol, yield = 4.9%) as a white solid. LC-MS (ESI): m / z: 377.1 [M+H] + . 1 H NMR(400MHz, DMSO-d6)δ:13.32(s,1H),8.30(d,J=7.2Hz,1H),7.59–7.52(m,2H),6.62(s,2 H),5.68–5.63(m,1H),5.25(d,J=10.6Hz,1H),2.09(s,3H),1.98(s,3H),1.97–1.90(m,3H).
[0204] Example 5:
[0205] Synthesis of compound 2i
[0206] Step 1
[0207] To a solution of compound 2i-1 (2.5 g, 11.84 mmol) and 3,4-dihydro-2H-pyran (2.17 mL, 23.69 mmol) in CH2Cl2 (25 mL) was added 4-methylbenzenesulfonic acid hydrate (0.23 g, 1.18 mmol). The resulting mixture was stirred at 25 ° C for 2 hours. LCMS showed that the starting material was consumed and the desired product was formed. The mixture was concentrated under reduced pressure to dryness to obtain a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: EtOAc = 0 to 5%) to obtain compound 2i-2 (3.3 g, 11.18 mmol, yield = 94.4%) as a white solid.
[0208] Step 2
[0209] To a mixture of compound 2i-2 (900 mg, 3.05 mmol), benzylamine (0.35 mL, 3.20 mmol), sodium 2-methylpropan-2-ol (879.02 mg, 9.15 mmol) and Xantphos (352.85 mg, 0.61 mmol) in toluene (10 mL) was added Pd2(dba)3 (279.2 mg, 0.30 mmol), the mixture was degassed and purged with N2 three times, and stirred at 105 ° C under N2 for 18 hours. LCMS showed that the starting material was consumed and the desired product was formed. The mixture was poured into water (10 mL) and extracted three times with EtOAc (30 mL). The combined organic phase was washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness under reduced pressure to give a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: EtOAc = 0 to 15%) to afford compound 2i-3 (0.7 g, 2.18 mmol, yield = 71.4%) as a yellow oil.
[0210] Step 3
[0211] To a mixture of compound 2i-3 (700 mg, 2.18 mmol) in MeOH (8 mL) was added palladium (0) (200 mg, 0.19 mmol), the mixture was degassed and purged with H2 3 times, and stirred at 25 ° C under H2 for 18 hours. LCMS showed that the starting material was consumed and the desired product was formed. The reaction mixture was filtered through a celite pad, the celite pad was washed twice with MeOH (10 mL), and the filtrate was concentrated to dryness under reduced pressure to give a crude product. The crude product was purified by silica gel chromatography (eluent: petroleum ether: EtOAc = 0-20%) to give compound 2i (350 mg, 1.51 mmol, yield = 69.5%) as a white solid. LC-MS (ESI): m / z = 232.2 [M + H] + .
[0212] Example 6:
[0213] The following compounds were prepared according to the similar operating procedures of Examples 1 to 5:
[0214] Biological examples:
[0215] Example X: ADP-Glo Enzymatic Assay
[0216] The recombinant human Myt1 kinase assay and the commercially available ADP-Glo assay (ADP-Glo from Promega) were used. TM Myt1 kinase activity is measured using a kinase assay (#G9101) that measures ATP hydrolysis. Briefly, 5 μL of recombinant human Myt1 (full-length PKMYT1 recombinant human protein expressed in insect cells from Thermo Fisher Scientific (#A32902)) was prepared in reaction buffer (70 mM HEPES, 3 mM MgCl2, 3 mM MnCl2, 50 pg / ml PEG 20000, 3 μM sodium vanadate, 1.2 mM DTT) and added to a 384-well, white polystyrene, flat-bottom, untreated microplate. Next, 5 μL of compound was added to the microplate, which was briefly vortexed and incubated at room temperature for 15 minutes. Ultrapure adenosine triphosphate (ATP) solution (from Promega's ADP-Glo kit) was diluted in reaction buffer, and 5 mL of the dilution was added to the microplate, briefly centrifuged, and incubated at room temperature for 60 minutes. After 60 minutes of incubation, 5 μL of ADP-Glo reagent was added, the microplate was briefly centrifuged, sealed, and incubated at room temperature for 40 minutes in the dark. Subsequently, 10 μL of kinase assay reagent was added to each well, the microplate was briefly centrifuged, sealed, and incubated at room temperature for 40 minutes in the dark. Luminescence values were read using Envision. The IC value for each test inhibitor compound was calculated. 50 and maximum inhibition percentage.
[0217] Example Y: NanoBret detection
[0218] HEK293 cells transiently expressing the NanoLuc-PKMYT1 fusion construct were seeded into wells of a 384-well plate. Cells were pretreated with the NanoBRET tracer and then treated with the test compound for 2 hours. BRET signals were measured at 450 nm and 610 nm on an Envision multilabel reader. IC values were calculated using GraphPad Prism with a 4-parameter nonlinear regression model. 50 Value and plot IC 50 curve.
[0219] Example Z: Cell proliferation assay
[0220] Cancer cell lines expressing normal or elevated CCNE1 levels were evaluated for sensitivity to test compounds in a cell proliferation assay. Cell lines were maintained in ATCC-recommended medium, 10% FBS, 1% P / S, in a humidified 5% CO2 tissue culture incubator. All test compounds were supplied as 20 mM DMSO stocks.
[0221] On day 0, CCNE1-wt and CCNE1-amp cells were seeded in 384-well plates and cultured in a humidified 5% CO2 tissue culture incubator for 16-24 hours. On day 1, test compounds were dispensed into the wells at the specified concentrations (n=2), and the volume of DMSO was normalized to the top level volume. Compound-treated plates were cultured in a humidified 5% CO2 tissue culture incubator for 7 days.
[0222] On day 7, the plates were removed from the tissue culture incubator and allowed to equilibrate to room temperature. Relative inhibition was assessed by adding CellTiter-Glo reagent, and data were plotted as a percentage of the DMSO control for each compound in each cell line. IC was calculated using a 4-parameter nonlinear regression model (GraphPad Prism). 50 value.
[0223] Table 1: Cell viability data
[0224] From the data results in Table 1, it can be seen that the compound of the present invention can indeed bind to Myt1 in cells in the NanoBRET assay, and exhibits the activity of inhibiting cell proliferation in CCNE1-amp breast cancer cells HCC1569.
[0225] Although the present invention has been described and illustrated with reference to specific embodiments of the present invention, these descriptions and illustrations are not restrictive. Those skilled in the art will understand that various changes may be made and equivalents substituted without departing from the true spirit and scope of the present invention as defined by the appended claims. The illustrations may not necessarily be drawn to scale. Due to manufacturing processes and tolerances, there may be differences between the process reproduction in the present invention and the actual equipment. There may be other embodiments of the present invention that are not specifically described. This specification and drawings should be regarded as illustrative and not restrictive. Modifications may be made to make specific circumstances, materials, compositions of matter, methods or processes suitable for the objectives, spirit and scope of the present invention. All such modifications are intended to be within the scope of the appended claims. Although the methods disclosed herein have been described with reference to specific operations performed in a specific order, it should be understood that these operations can be combined, subdivided or reordered to form equivalent methods without departing from the teachings of the present invention. Accordingly, unless specifically indicated herein, the order and grouping of operations are not limitations of the present invention.
Claims
1. A compound of formula (I), in: Ring A is indazolyl; R1 is halogen, hydroxy, oxo, cyano, nitro, amine, alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -B(OH)2, -S(=O)-alkyl, -S(=O)2-alkyl, -S(=O)NH2, -S(=O)2NH2, -P(=O)-dialkyl, -C(=O)NH2, -C(=O)alkyl, -C(=O)alkoxy, boric acid, heterocyclyl, aryl or heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by a group selected from the group consisting of halogen, hydroxy, amine, alkyl, aryl, heteroaryl or heterocyclyl; Z1 is a direct key; Z2, Z3 and Z4 are independently CR a or N; Z5 is -C(=O)-, N or CR a ; Z6 and Z7 are independently CR a or N; wherein the position of the double bond on the bicyclic ring to which ring A is attached changes as Z2 to Z7 are N or -C(=O)-; and wherein R a is hydrogen, alkyl, hydroxyalkyl, alkenyl, alkynyl, amino or cyano; X is -C(=O)- or NR c , where R c is a heterocyclic group, an aryl group or a heteroaryl group; wherein the heterocyclic group, the aryl group or the heteroaryl group is optionally substituted by a group selected from the following: a hydroxyl group, an amine group, an alkyl group, an aryl group, a heteroaryl group or a heterocyclic group; R2, R3 and R4 are independently hydrogen, alkyl, -C(=O)NH2, amine, alkylamino or dialkylamino; wherein the alkyl, amine, alkylamino or dialkylamino is optionally substituted by a group selected from the group consisting of hydroxyl, amine, alkyl, aryl, heteroaryl or heterocyclic; R5 is alkyl, amine, alkylamino or dialkylamino; wherein the alkyl, amine, alkylamino or dialkylamino is optionally substituted by a group selected from the group consisting of hydroxyl, amine, alkyl, aryl, heteroaryl or heterocyclic; and R5 and R4 together form a 5- to 8-membered heteroaromatic or heterocyclic ring; wherein the heteroaryl or heterocyclic group is optionally substituted by a group selected from the following: halogen, cyano, alkoxy, carbonyl, hydroxyl, amine, alkyl, aryl, heteroaryl, heterocyclic or cycloalkyl; R6 is hydrogen, amine, alkylamino or dialkylamino; or, R6 and Z3 to which it is attached together form -C(=O)-; or, R6 and X together form a 5- to 8-membered heteroaromatic or heterocyclic ring; wherein the heteroaromatic or heterocyclic ring is optionally substituted by a group selected from the following: halogen, cyano, alkoxy, carbonyl, hydroxyl, amine, alkyl, aryl, heteroaryl, heterocyclyl or cycloalkyl; n is 3 or 4; or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, racemate, prodrug, solvate or hydrate thereof.
2. The compound according to claim 1, which has the formula (IC), in: Ring A is indazolyl; each R1 is independently halogen, hydroxy, oxo, cyano, nitro, amine, alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, -B(OH)2, -S(=O)-alkyl, -S(=O)2-alkyl, -S(=O)NH2, -S(=O)2NH2, -P(=O)-dialkyl, -C(=O)NH2, -C(=O)alkyl, -C(=O)alkoxy, boric acid, heterocyclyl, aryl or heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, haloalkyl, haloalkoxy, halocycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by a group selected from the group consisting of halogen, hydroxy, amine, alkyl, aryl, heteroaryl or heterocyclyl; n is 3 or 4; X is -C(=O)- or NR c , where R c is a heterocyclic group, an aryl group or a heteroaryl group; R5 is an alkyl, an amine, an alkylamino or a dialkylamino group; wherein the alkyl, an amine, an alkylamino or a dialkylamino group is optionally substituted by a group selected from the following: a hydroxyl, an amine, an alkyl, an aryl, a heteroaryl or a heterocyclic group; Ring B and Ring C do not exist at the same time; Ring B is a 5- to 8-membered heteroaromatic ring or a heterocyclic group; wherein the heteroaromatic ring or The heterocyclyl group is optionally substituted by a group selected from the group consisting of halogen, cyano, alkoxy, carbonyl, hydroxy, amine, alkyl, aryl, heteroaryl, heterocyclyl or cycloalkyl; and Ring C is a 5- to 8-membered heteroaromatic or heterocyclic ring; wherein the heteroaromatic or heterocyclic ring is optionally substituted by a group selected from the following: halogen, cyano, alkoxy, carbonyl, hydroxyl, amine, alkyl, aryl, heteroaryl, heterocyclyl or cycloalkyl.
3. The compound according to any one of claims 1 to 2, wherein X is -C(=O)-.
4. The compound according to any one of claims 1 to 2, wherein X is NR c , where R c is a heterocyclic group, an aryl group or a heteroaryl group.
5. The compound according to any one of claims 1 to 4, wherein R1 is selected from the group consisting of: -CH3, -CN, -OH, -OCH3, -F, -Cl, -Br, -CF3, -CCl3, -NO2, -B(OH)2, 6. The compound according to claim 1, wherein Z1 is a direct bond; Z3 is C; at least one of Z2 and Z4 is N; Z5 is -C(=O)-, N or CR a , where R a is hydrogen, alkyl, hydroxyalkyl, alkenyl, alkynyl, amino or cyano; Z6 and Z7 are independently C or N.
7. The compound according to claim 1, wherein R2, R3 and R4 are independently hydrogen, alkyl, -C(=O)NH2 or amine; R5 is alkyl or amine; R6 is hydrogen or amine.
8. The compound according to claim 2, wherein R5 is an alkyl group or an amino group.
9. The compound according to claim 2, wherein X is -C(=O)-; R5 is an alkyl group or an amine group; Ring B is a 6-membered or 7-membered heteroaromatic or heterocyclic ring; wherein the heteroaromatic or heterocyclic ring is optionally substituted by a group selected from the following: halogen, cyano, alkoxy, carbonyl, hydroxyl, amine, alkyl, aryl, heteroaryl, heterocyclyl or cycloalkyl; and Ring C does not exist.
10. The compound according to claim 1, which is selected from:
11. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof, and a pharmaceutically acceptable carrier or excipient.
12. Use of a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof for the manufacture of a medicament for treating cancer in an individual in need thereof.
13. The use according to claim 12, wherein the compound or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof is co-administered to the subject with a second anticancer agent, surgical therapy, ionizing radiation or a combination thereof.
14. The use according to claim 12, wherein the second anticancer agent is selected from: targeted cancer drugs such as trastuzumab, ramucirumab, bevacizumab, everolimus, tamoxifen, toremifene, fulvestrant, anastrozole, exemestane, lapatinib, letrozole, pertuzumab, adotrastuzumab emtacin, palbociclib, cetuximab, panitumumab, zulafalib, regorafenib, imatinib mesylate, lanreotide acetate, sunitinib, regorafenib, denosumab, alitretinoin, sorafenib, pazopanib, temsirolimus, everolimus, tretinoin, dasatinib, nilotinib, Bosutinib, rituximab, alemtuzumab, ofavumab, obinumab, ibrutinib, idexib, brinumab, soranib, crizotinib, erlotinib, gefitinib, afatinib dimaleate, ceritinib, ramucirumab, nivolumab, pembrolizumab, osimertinib, and lecithinib; alkylating agents, such as busulfan, chlorambucil, cyclophosphamide, ifosfamide, melphalan, mechlorethamine, streptozotocin, thiotepa, uracil mustard, triethylenemelamine, temozolomide, and 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU); antibiotics or plant alkaloids, such as actinomycetes hormones or steroids, such as 5α-reductase inhibitors, aminoglutethimide, anastrozole, bicalutamide, chlortetracycline, diethylstilbestrol (DES), drostanolone, estramustine, ethinyl estradiol, flutamide, fluoxymesterone, goserelin, hydroxyprogesterone, letrozole, leuprolide, medroxyprogesterone acetate, acetylcholine, dapoxetine, tadalafil, oxadiazine, chlortetracycline, dapoxetine, chlortetracycline, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine, dapoxetine megestrol acetate, methylprednisolone, methyltestosterone, mitotane, nilutamide, prednisolone, arzoxifene (SERM-3), tamoxifen, testolactone, testosterone, triamcinolone, and Zoladex; synthetic preparations such as all-trans retinoic acid, carmustine (BCNU), carboplatin (CBDCA), lomustine (CCNU), cis-diamminedichloroplatinum (cisplatin), dacarbazine, golidel, altretinoin, hydroxyurea, levamisole, mitoxantrone, o,p'-dichlorodiphenyldichloroethane (o,p'-DDD) (also known as mitotane), oxaliplatin, porfimer sodium, procarbazine, and imatinib mesylate antimetabolites, such as chlorodeoxyadenosine, cytosine arabinoside, 2'-deoxycoformycin, fludarabine phosphate, 5-fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (5-FUdR), gemcitabine, camptothecin, 6-mercaptopurine, methotrexate, and thioguanine; and biologics, such as interferon alpha, bacillus Calmette-Guérin (BCG), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and Herceptin.
15. The use according to claim 12, wherein the cancer is a cardiac cancer, such as a sarcoma (e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma), a myxoma, a rhabdomyoma, a fibroma, a lipoma, and a teratoma; Lung cancer, such as bronchial cancer (e.g., squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, and adenocarcinoma), alveolar cancer (e.g., bronchiolar carcinoma), bronchial adenoma, sarcoma, lymphoma, chondroitinoma, and mesothelioma; Gastrointestinal cancer, such as esophageal cancer (e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma), gastric cancer (e.g., lymphoma and leiomyosarcoma), pancreatic cancer (e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid, and vipoma), small intestine cancer (e.g., adenocarcinoma, lymphoma, carcinoid, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma) , colorectal cancer (e.g., adenocarcinoma, ductal adenoma, villous adenoma, hamartoma, and leiomyoma); genitourinary tract cancers, such as kidney cancer (e.g., adenocarcinoma, Wilms' tumor [Nephroblastoma], lymphoma, and leukemia), bladder and urethral cancer (e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma), prostate cancer (e.g., adenocarcinoma and sarcoma), testicular cancer (e.g., spermatoma, teratoma, embryonal tumor, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, and lipoma); liver cancers, such as hepatocellular carcinoma (e.g., hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma; Bone cancers, such as osteogenic sarcomas (e.g., osteosarcomas), fibrosarcomas, malignant fibrous histiocytomas, chondrosarcomas, Ewing's sarcomas, malignant lymphomas (e.g., reticulum cell sarcomas), multiple myeloma, malignant giant cell tumors, chordomas, osteochondromas (e.g., osteochondroma exostoses), benign enchondromas, chondroblastomas, chondromyxofibromas, osteoid osteomas, and giant cell tumors; Nervous system cancers, such as skull cancers (e.g., osteomas, hemangiomas, granulomas, xanthomas, and osteitis deformities), meningeal cancers (e.g., meningiomas, spinal cord cancers, sarcomas and gliomas), brain cancers (e.g., astrocytomas, medulloblastomas, gliomas, ependymomas, blastomas (pinealomas), glioblastomas multiforme, oligodendrogliomas, schwannomas, retinoblastomas, and congenital tumors), spinal neurofibromas, meningiomas, gliomas, and sarcomas; gynecological cancers, such as uterine cancer (e.g., endometrial cancer), cervical cancer (e.g., cervical cancer and preneoplastic cervical dysplasia), ovarian cancer (e.g., ovarian cancer [e.g., serous cystadenocarcinoma, mucinous cystadenocarcinoma and carcinoma of unspecified type], granulosa cell tumor, Stoli-Redig cell tumor, dysgerminoma, and malignant teratoma), vulvar cancer (e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma), vaginal cancer (e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma [e.g., embryonal rhabdomyosarcoma], and fallopian tube cancer); blood cancers, such as blood cancers (myeloid leukemias [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, and myelodysplasia), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma]; skin cancers, such as malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; adrenal gland cancers, such as neuroblastoma; or breast cancer.
16. A process for preparing a compound of formula (I) as defined in any one of claims 1 to 10 or a pharmaceutically acceptable salt, geometric isomer, enantiomer, diastereomer, prodrug or solvate thereof, It contains: a. Make the compound of formula (II) and pyridine of formula (III) Reaction in the presence of a catalyst to obtain a compound of formula (IV) wherein Ring A, R1 and n are as defined in claim 1, Hal is halogen; R A is an alkyl group; b. reacting a compound of formula (IV) with a coupling agent containing a cyano group to obtain a compound of formula (I') The compound of formula (I') is subjected to an acylation reaction in the presence of an acid to obtain the compound of formula (I).
Citation Information
Patent Citations
Compound for inhibiting programmed cell death and preparation method thereof
CN115806557A
Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
US20230122909A1
Novel bicyclic compounds
WO2022087371A1
Novel heterocyclic compounds
WO2022087375A1
Combination therapies including MYT1 inhibitors
WO2022213204A1
